Thursday, January 17, 2013 9:07:35 AM
I just realized that the email is on my other computer at our main office and I have no way of accessing that information right now. However, I can try to relay the gist of the message from memory.
About two weeks ago, Mr. Davis Caskey (from ECR, VP, I believe) were involved in an email exchange about the future of the Lodrane ER drugs coming back to market. The bottom line is that the FDA (at the time) had not yet even responded to ECR's preliminary information filing regarding drug development procedures. Mr. Caskey indicated to me that although the FDA had sixty days to complete the response - they were running on almost 160 days, without any information/response.
According the Mr. Caskey, the debt crisis is creating uncertainties for them (and wondering if the FDA will receive funding to appropriately respond to drug applications). In light of the extremely long FDA response times that ECR is being presented with, Mr. Caskey indicated to me that ECR will be meeting early in 2013 to evaluate whether or not to proceed with the continued development of the Lodrane ER line. Citing a $2,000,000 initial fee, plus other costs and increased waiting times, Mr. Caskey believes that the development of the program will have to be re-evaluated from a cost perspective.
I will be glad to forward his email as soon as I get back to the main office. He has indicated to me a number of times that he does not mind my sharing email communication with other investors.
I hope everyone has a great day.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM